Published July 26, 2018
Decades of work on chronic obstructive pulmonary disease (COPD) at the Jacobs School of Medicine and Biomedical Sciences and the Veterans Affairs Western New York Healthcare System have yielded extraordinary information about the bacterial pathogen that does the most harm to patients.
The results, published in March in the Proceedings of the National Academy of Sciences, provide the first insights into how nontypeable Haemophilus influenzae (NTHi) lives and adapts to its host in real time over months and even years.
“By helping us understand how this pathogen survives in a hostile environment in human airways, this research is helping us develop ways to eradicate the pathogen to improve the lives and health of people with COPD,” says senior author Timothy F. Murphy, MD, SUNY Distinguished Professor of medicine and senior associate dean for clinical and translational research.
Human airways include the nose, nasal cavities, the mouth, larynx, trachea and bronchial passageways.
NTHi is the source of much of the misery that COPD patients endure. It is an exceptionally formidable adversary because strains adapt to each host, Murphy says.
The researchers had 269 different strains of the pathogen to study after taking samples each month for 15 years from 192 Western New York patients with COPD.
“People with COPD carry this organism in their lower airways for months to years,” Murphy says. “And since it’s a pathogen that doesn’t belong there, it causes all kinds of problems.”
“It’s a hostile environment: The little hairs called cilia are continuously trying to get it out of the airway; that’s what makes patients cough,” he adds.
“The immune system is bombarding it with antibodies and macrophages that are trying to eat it up, and with antimicrobial peptides, small molecules that are looking to punch holes in the bacteria. All of these things make it a challenge for these bacteria to live in the human airways.”
And yet they do survive and even thrive. To find out why and how NTHi survives, and how it might be overcome, Murphy and his colleagues were awarded a National Institutes of Health (NIH) grant in 2013.
It was part of a continuous 28-year-long grant from the NIH to Murphy and his longtime collaborator, Sanjay Sethi, MD, professor of medicine, chief of pulmonary, critical care and sleep medicine and a co-author on the paper.
“Studies of this pathogen up until now have been looking at strains grown in labs or stored in freezers,” Murphy says. “The power of our study is that we have 269 strains of the pathogen and we can see what it looked like when the patient first acquired the strain and how it changed its genes to survive in the unique environment of the human airways.”
Those genetic changes are key, he says, to determining where the pathogen’s vulnerabilities lie and what the best strategy might be to eradicate it.
The ability to efficiently sequence the genome of the pathogen and analyze it was critical to the success of the research, Murphy notes.
“Not only were we able to look at what the genes looked like when the patient acquired the pathogen, but we followed these patients every month,” he adds. “One bacterium lived in a patient for four years. The genomes are like a looking glass, revealing the pathogen’s secrets to us by showing us how it changed its genes through the years.”
What the researchers found is that the Haemophilus influenzae turns genes on and off — it’s constantly changing which genes are activated based on the environment in the airway.
Since the lower airways are nutritionally deprived, for example, the research demonstrated that the pathogen would activate all of its mechanisms to try and scavenge nutrients like iron that it needs to survive, Murphy notes.
That information is critical to potentially developing a vaccine or a treatment.
“Now that we’re beginning to understand how the bacterium is able to survive, we can use these molecules that come from the genes we found as drug targets to eradicate the bacterium from the airways,” Murphy says.
“The beauty of this approach is that a new drug can be targeted specifically to an antigen, allowing selective eradication of the pathogen without disturbing the normal flora.”
Murphy emphasizes the work resulted from true collaboration — not just between Jacobs School colleagues — but also with the study’s other co-authors.
They include longtime research partners Melinda Pettigrew, PhD, professor of epidemiology at Yale University and an expert in the molecular epidemiology of respiratory tract infections; and Hervé Tettelin, PhD, associate professor of microbiology and immunology at the University of Maryland School of Medicine and an international authority on microbial genomics.
The majority of the laboratory work was performed at UB, with most of the genomic sequencing performed by the genomics core at UB’s New York State Center of Excellence in Bioinformatics and Life Sciences.
In addition to the NIH grant to Murphy, Pettigrew and Tettelin, the work was also funded in part by the Department of Veterans Affairs and by the Clinical and Translational Science Award to UB.
Both Sethi and Murphy note the most important collaborators were the 192 patients who visited their COPD study clinic monthly and consistently provided samples to the researchers over the course of the 15-year study.
“We are first and foremost grateful to these patients, who received close medical attention while they were contributing to the study and without whom this study could not have been done,” Sethi says.
Other Jacobs School co-authors are:
Both are performing their thesis research in Murphy’s laboratory.
Other co-authors are: